Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ranpirnase - Tamir Biotechnology

Drug Profile

Ranpirnase - Tamir Biotechnology

Alternative Names: Amphibian ribonuclease A; Onconase; P-30 protein - Alfacell; P-30 ribonuclease

Latest Information Update: 24 Apr 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Alfacell Corporation
  • Developer Alfacell Corporation; Tamir Biotechnology
  • Class Antineoplastics; Antivirals; Eye disorder therapies; Ribonucleases
  • Mechanism of Action Apoptosis stimulants; Protein synthesis inhibitors; Ribonuclease replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Mesothelioma; Ebola virus infections
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase I/II Genital warts
  • Preclinical Ebola virus infections; HIV infections; Zika virus infection
  • Discontinued Acute myeloid leukaemia; Brain cancer; Chronic lymphocytic leukaemia; Mesothelioma; Neuroblastoma; Non-small cell lung cancer; Pancreatic cancer; Prostate cancer; Renal cell carcinoma

Most Recent Events

  • 24 Apr 2019 Ranpirnase is available for licensing as of 24 Apr 2019. http://tamirbio.com/partnering/
  • 08 Aug 2017 Ranpirnase receives Orphan Drug status for Ebola virus infections in USA
  • 08 Mar 2017 Efficacy data from a phase I/II trial in Genital warts and Human papillomavirus infections released by Tamir Biotechnology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top